Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
105.25
-3.42 (-3.15%)
At close: Jun 8, 2026, 4:00 PM EDT
105.00
-0.25 (-0.24%)
After-hours: Jun 8, 2026, 4:10 PM EDT
Palvella Therapeutics Employees
Palvella Therapeutics had 29 employees as of December 31, 2025. The number of employees increased by 15 or 107.14% compared to the previous year.
Employees
29
Change (1Y)
15
Growth (1Y)
107.14%
Revenue / Employee
n/a
Profits / Employee
-$1,699,897
Market Cap
1.51B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 29 | 15 | 107.14% |
| Dec 31, 2024 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Ascentage Pharma Group International | 767 |
| Syndax Pharmaceuticals | 298 |
| KalVista Pharmaceuticals | 275 |
| Capricor Therapeutics | 231 |
| Monte Rosa Therapeutics | 187 |
| AnaptysBio | 104 |
| Taysha Gene Therapies | 99 |
PVLA News
- 5 days ago - Palvella Therapeutics completes Qtorin pre-new drug application meeting with FDA - TheFly
- 5 days ago - Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations - GlobeNewsWire
- 6 days ago - Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 - GlobeNewsWire
- 12 days ago - Palvella Therapeutics issued patent by USPTO for Qtorin pitavastatin program - TheFly
- 12 days ago - Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043 - GlobeNewsWire
- 18 days ago - Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards - GlobeNewsWire
- 19 days ago - Palvella Therapeutics announces new data from SELVA, TOIVA studies - TheFly
- 19 days ago - Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations - GlobeNewsWire